Pharsight

Argatroban In Sodium Chloride patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7687516 CIPLA Alcohol free formulation of argatroban
Sep, 2027

(3 years from now)

US7589106 CIPLA Alcohol free formulation of argatroban
Sep, 2027

(3 years from now)

Argatroban In Sodium Chloride is owned by Cipla.

Argatroban In Sodium Chloride contains Argatroban.

Argatroban In Sodium Chloride has a total of 2 drug patents out of which 0 drug patents have expired.

Argatroban In Sodium Chloride was authorised for market use on 29 June, 2011.

Argatroban In Sodium Chloride is available in injectable;intravenous dosage forms.

Argatroban In Sodium Chloride can be used as method of treating an argatroban treatable condition, method of treating thrombosis.

The generics of Argatroban In Sodium Chloride are possible to be released after 26 September, 2027.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ARGATROBAN ingredient

Market Authorisation Date: 29 June, 2011

Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ARGATROBAN IN SODIUM CHLORIDE before it's drug patent expiration?
More Information on Dosage

ARGATROBAN IN SODIUM CHLORIDE family patents

Family Patents